Ozempic maker Novo Nordisk gets another downgrade. The end's in sight for its duopoly status, says TD Cowen.
诺和诺德(US:NVO) MarketWatch·2026-03-10 17:48公司动态 - 诺和诺德于周二遭到券商下调评级[1] 业务与竞争格局 - 分析师认为公司在糖尿病和减肥药领域的双头垄断地位正面临威胁[1]
诺和诺德(US:NVO) MarketWatch·2026-03-10 17:48